Literature DB >> 3137271

Mechanism of ciprofloxacin resistance in Pseudomonas aeruginosa.

G W Kaatz1, S M Seo.   

Abstract

We studied the mechanism(s) of resistance to ciprofloxacin arising in a clinical strain of Pseudomonas aeruginosa and in a laboratory-derived isolate of that strain. Higher concentrations of ciprofloxacin were required to interfere with DNA synthesis in resistant isolates compared with the parent strain, a finding indicating a relative insensitivity of DNA gyrase to ciprofloxacin. Reduced uptake of ciprofloxacin was seen in one isolate and may have contributed to its ciprofloxacin resistance but was not associated with alterations in outer or cytoplasmic membrane proteins, a result suggesting that such changes are not required to decrease uptake of fluoroquinolones into cells. No evidence for plasmid-mediated resistance was found, and no ciprofloxacin-inactivating activity was detected in sonic extracts of resistant organisms. In these isolates, resistance to ciprofloxacin was likely the result of more than one mutation, because single-step mutations conferring such high-level resistance were not found in the parent strain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137271     DOI: 10.1093/infdis/158.3.537

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  In vitro antibiotic resistance in bacterial keratitis in London.

Authors:  S J Tuft; M Matheson
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.

Authors:  E Bingen; E Denamur; B Picard; P Goullet; N Lambert-Zechovsky; P Foucaud; J Navarro; J Elion
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

3.  A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

Authors:  L J Piddock; M C Hall; F Bellido; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Authors:  J M Diver; T Schollaardt; H R Rabin; C Thorson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

5.  Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.

Authors:  Nivedita Shetty; Patricia Ahn; Heejun Park; Sonal Bhujbal; Dmitry Zemlyanov; Alex Cavallaro; Sharad Mangal; Jian Li; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2018-08-03       Impact factor: 4.939

6.  Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin.

Authors:  G Rådberg; L E Nilsson; S Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

7.  Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon.

Authors:  K Poole; K Krebes; C McNally; S Neshat
Journal:  J Bacteriol       Date:  1993-11       Impact factor: 3.490

8.  Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells.

Authors:  I García; A Pascual; M C Guzman; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 9.  Bacterial resistance to fluoroquinolones: lessons to be learned.

Authors:  P Ball
Journal:  Infection       Date:  1994       Impact factor: 3.553

10.  Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.

Authors:  G G Zhanel; J A Karlowsky; M H Saunders; R J Davidson; D J Hoban; R E Hancock; I McLean; L E Nicolle
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.